Background: Immunotherapy (IO) is expected to become a part of standard neoadjuvant therapy for early-stage, triple-negative breast cancer. However, only a minority of patients benefit from the addition of IO to standard neoadjuvant chemotherapy (NACT). Biomarkers of IO response in…
Background: Dynamic contrast-enhanced (DCE) MRI has long been used in the diagnosis and treatment planning of cancers. Chief among its use is the identification of tumors in soft tissues, where the tumor progression-induced angiogenic changes result in leaky vasculature which…
Introduction: Chemotherapy for early stage breast cancer is associated with a plethora of side effects including fatigue, alopecia, neuropathy, cardiotoxicity, myelosuppression, gastrointestinal symptoms, fertility issues, memory impairment, and mouth sores. As a result, a significant number of patients (pts) require…
Transforming existing -omics data with proprietary systems biology techniques to capture metabolic variation in tumors to predict, prognosticate and stratify patient response
Spatially resolved tumor analysis uncovering tumor metabolic and biophysical diversity
In silico modeling in patient tumors to assess and optimize the impact of drug delivery on tumor response
Proprietary image segmentation models for various imaging modalities and pathology slides to capture tumor and tumor microenvironment
Novel Signatures for Immunotherapies beyond PD-1 & PD-L1 capturing insights on spatial metabolism of tumor and lymphyocytes
Discovery of differentiated and multi-scale biomarkers to add actionable insights
Novel image based signatures to predict response at a voxel level going beyond traditional metrics
SOLUTIONS
RESOURCES
©SimBioSys